Lupeol
Catalog No: CFN98913
1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent.
2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade.
3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses.
4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo.
5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia.
6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway.
7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma.
Galangin
Catalog No: CFN98918
Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of CYP1A1 activity. Galangin has anti-proliferation, anti-metastatic, anti-inflammatory, vasorelaxant, antiviral, anti-allergic inflammatory,anti-obesity effects; it may be a potential candidate for the treatment of vitiligo. Galangin can inhibit Topo I activity and reduce the unwinding rate of single stranded DNNA in tumor cells, which plays an important role in induction of A549 and H46 cell apoptosis. Galangin shows an inhibitory effect on acetylcholinesterase (AChE) activity with the IC(50) of 120 microM;
it also inhibits ERK, NF-κB-p65 and proinflammatory gene expression.
